tradingkey.logo
tradingkey.logo
Search

New Data From Helios-B Phase 3 Study Demonstrate Lower Rates Of Gastrointestinal Events In ATTR-CM Patients Treated With Vutrisiran

ReutersSep 29, 2025 10:59 PM
facebooktwitterlinkedin
View all comments0

- Alnylam Pharmaceuticals Inc ALNY.O:

  • NEW DATA FROM HELIOS-B PHASE 3 STUDY DEMONSTRATE LOWER RATES OF GASTROINTESTINAL EVENTS IN ATTR-CM PATIENTS TREATED WITH VUTRISIRAN

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI